Drug:
Reaction: DERMATITIS ATOPIC
20260101 - 20261231
No. 101 - 200
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 101 | 26549517 |
US |
31 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 102 | 26549520 |
US |
16 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 103 | 26549528 |
US |
44 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 104 | 26549544 |
US |
61 | 2 |
Dermatitis atopic, Erythema, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 105 | 26549552 |
US |
16 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 106 | 26549553 |
US |
3 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 107 | 26549560 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 108 | 26549561 |
US |
63 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 109 | 26549562 |
US |
4 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 110 | 26549566 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 111 | 26549587 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 112 | 26549593 |
US |
29 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 113 | 26549596 |
US |
44 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 114 | 26549604 |
US |
1 | 2 |
Dermatitis, Ocular hyperaemia, Periorbital inflammation, Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 115 | 26549620 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 116 | 26549622 |
US |
53 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 117 | 26549647 |
US |
1 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 118 | 26549652 |
US |
34 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 119 | 26549664 |
US |
40 | 2 |
Dermatitis atopic, Injection site erythema, Injection site pain, |
||||
DUPILUMAB, |
||||
| 120 | 26549670 |
US |
89 | 1 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 121 | 26549674 |
US |
48 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, LEVONORGESTREL, |
||||
| 122 | 26549682 |
US |
23 | 2 |
Dermatitis atopic, Pruritus, Product dose omission issue, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 123 | 26549683 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 124 | 26549691 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 125 | 26549693 |
US |
2 | |
Dermatitis atopic, Product ineffective, |
||||
DUPILUMAB, |
||||
| 126 | 26549705 |
US |
19 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 127 | 26549711 |
US |
33 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 128 | 26549721 |
US |
17 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 129 | 26549724 |
US |
14 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 130 | 26546740 |
US |
56 | 1 |
Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 131 | 26546804 |
US |
14 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 132 | 26546805 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 133 | 26546806 |
US |
8 | 1 |
Dermatitis atopic, Rash, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 134 | 26546823 |
US |
30 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 135 | 26546861 |
US |
12 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 136 | 26546884 |
US |
32 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 137 | 26546912 |
US |
1 | |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 138 | 26546954 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 139 | 26546957 |
US |
47 | 2 |
Dermatitis atopic, Erythema, Pruritus, Skin swelling, Product dose omission in error, |
||||
DUPILUMAB, LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ONABOTULINUMTOXINA, BUPROPION, DAPSONE GEL, 5%, DAPSONE, DASPONE, DICLOFENAC, DICLOFENAC SODIUM, FAMOTIDINE, DULOXETINE HYDROCHLORIDE, DULOXETINE, |
||||
| 140 | 26546976 |
US |
44 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 141 | 26546983 |
US |
25 | 2 |
Dermatitis atopic, Illness, |
||||
DUPILUMAB, |
||||
| 142 | 26547075 |
US |
2 | |
Gastroenteritis viral, Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 143 | 26547100 |
US |
11 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 144 | 26547106 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 145 | 26547134 |
US |
1 | 2 |
Injection site reaction, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 146 | 26547140 |
US |
18 | 1 |
Dermatitis atopic, Asthma, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 147 | 26547141 |
US |
1 | |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, ERGOCALCIFEROL, |
||||
| 148 | 26547157 |
US |
13 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 149 | 26547167 |
US |
1 | |
Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 150 | 26547168 |
US |
1 | |
Dermatitis atopic, Inappropriate schedule of product administration, Fear of injection, |
||||
DUPILUMAB, |
||||
| 151 | 26547224 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, Product storage error, |
||||
DUPILUMAB, |
||||
| 152 | 26547272 |
US |
14 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 153 | 26547338 |
US |
29 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 154 | 26547344 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 155 | 26547396 |
US |
5 | 2 |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 156 | 26547402 |
US |
21 | 2 |
COVID-19, Conjunctivitis, Dry eye, Dermatitis atopic, Dry skin, Skin exfoliation, Erythema, Rash, |
||||
DUPILUMAB, |
||||
| 157 | 26547412 |
US |
62 | 2 |
Dermatitis atopic, Urticaria, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 158 | 26547459 |
US |
20 | 2 |
Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 159 | 26547466 |
US |
70 | 1 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 160 | 26547469 |
US |
56 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 161 | 26547474 |
|||
Dermatitis atopic, Product dose omission issue, Off label use, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 162 | 26547502 |
US |
2 | |
Dermatitis atopic, Skin irritation, Pruritus, Drug ineffective, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 163 | 26547503 |
US |
68 | 2 |
Dysgeusia, Dermatitis atopic, Rash, Product preparation error, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 164 | 26547532 |
US |
10 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 165 | 26547592 |
US |
60 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 166 | 26547644 |
US |
39 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 167 | 26547667 |
US |
1 | |
Arthralgia, Dermatitis atopic, Pain, Arthralgia, |
||||
UPADACITINIB, |
||||
| 168 | 26547684 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 169 | 26547686 |
US |
15 | 1 |
Eye discharge, Dermatitis atopic, Eyelid margin crusting, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 170 | 26547874 |
US |
1 | |
Dermatitis atopic, Pruritus, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 171 | 26547877 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 172 | 26547925 |
US |
8 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 173 | 26547971 |
US |
7 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 174 | 26547973 |
US |
9 | 1 |
Dermatitis atopic, Asthma, Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 175 | 26548052 |
US |
66 | 2 |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 176 | 26548060 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 177 | 26548064 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 178 | 26548127 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, CETIRIZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE, CALCIUM, PROGESTERONE, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, DENOSUMAB, |
||||
| 179 | 26548148 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 180 | 26548150 |
US |
5 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 181 | 26548194 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 182 | 26548343 |
US |
21 | 1 |
Dermatitis atopic, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 183 | 26548374 |
US |
60 | 2 |
Psoriasis, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 184 | 26548453 |
US |
57 | 2 |
Ankle fracture, Dermatitis atopic, Pruritus, Rash erythematous, Skin swelling, |
||||
DUPILUMAB, |
||||
| 185 | 26548467 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 186 | 26548569 |
US |
2 | |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, BUPROPION, CELECOXIB, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM CAPSULE, DELAYED RELEASE, ESOMEPRAZOLE MAGNESIUM DIHYDRATE, ESOMEPRAZOLE MAGNESIUM DELAYED RELEASE CAPSULES, GABAPENTIN, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, SERTRALINE, SPIRONOLACTONE, |
||||
| 187 | 26548580 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 188 | 26548596 |
US |
2 | |
Dermatitis atopic, Erythema, Product dose omission issue, |
||||
DUPILUMAB, CETIRIZINE HYDROCHLORIDE, |
||||
| 189 | 26548611 |
US |
2 | |
Cellulitis, Arthralgia, Dermatitis atopic, Injection site pain, |
||||
DUPILUMAB, CEPHALEXIN, MAGNESIUM, NALTREXONE, PREDNISONE, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, ERGOCALCIFEROL, |
||||
| 190 | 26548666 |
US |
46 | 1 |
Pruritus, Product dose omission issue, Dermatitis atopic, |
||||
DUPILUMAB, ROSUVASTATIN, |
||||
| 191 | 26548670 |
US |
45 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 192 | 26548730 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 193 | 26548749 |
US |
78 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 194 | 26548751 |
US |
2 | |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, FEXOFENADINE HYDROCHLORIDE, |
||||
| 195 | 26548756 |
US |
64 | 1 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, LISINOPRIL, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 196 | 26548775 |
US |
13 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 197 | 26548784 |
US |
1 | |
Skin laxity, Skin wrinkling, Chronic spontaneous urticaria, Dermatitis atopic, Rash, |
||||
DUPILUMAB, ALBUTEROL SULFATE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, HYDROXYCHLOROQUINE SULFATE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, ABATACEPT, PREDNISONE, DENOSUMAB, CYCLOSPORINE, ERGOCALCIFEROL, CETIRIZINE HYDROCHLORIDE, |
||||
| 198 | 26542337 |
3 | ||
Immune thrombocytopenia, Mucosal inflammation, Dermatitis atopic, |
||||
LEVETIRACETAM, DUPILUMAB, CETIRIZINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE, |
||||
| 199 | 26542998 |
US |
65 | 1 |
Spinal operation, Thrombosis, Eye infection, Depression, Somnolence, Dry skin, Weight decreased, Injection site pain, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, GABAPENTIN, |
||||
| 200 | 26544491 |
EU |
3 | 2 |
Decreased appetite, Vaccination site erythema, Erythema, Rash, Upper respiratory tract infection, Infection, Mucous stools, Faeces discoloured, Nervousness, Weight gain poor, Dermatitis allergic, Lethargy, Vaccination site pain, Irritability, Vaccination site oedema, Nasopharyngitis, Dermatitis, Immune system disorder, Sleep disorder, Insomnia, Dermatitis atopic, Urticaria, Syncope, Seizure, Crying, Diarrhoea haemorrhagic, Abdominal pain upper, Muscle tightness, Vomiting, Vaccination site induration, Altered state of consciousness, Oral candidiasis, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28